FluoSphera has developed human multi-tissue systems that accurately replicate and analyze how a drug interacts with multiple organs. FluoSphera's technology addresses a critical gap in preclinical drug development by enabling the selection of the best candidate drugs based on their predicted systemic response in humans — ultimately determining clinical success for patients. By accurately predicting drug safety and efficacy, this approach reduces the likelihood of failure during clinical development, improves patient access to effective treatments, and minimizes the need for animal testing.
05.11.2024
Bio Europe in Stockholm hosts 33 Swiss companies (startupticker.ch)
31.05.2024
Swiss life science startups headed for San Diego (startupticker.ch)
03.07.2023
New FONGIT Innovation Initiation Program launched (startupticker.ch)
16.05.2023
FIF supports Fluosphera, Kylys Aesthetics and Consulto (startupticker.ch)
01.03.2023
FluoSphera secures $1 million pre-seed investment (startupticker.ch)
No milestones
No Jobs
No videos and documents
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Website:
fluosphera.com
Headquarter:
Plan-les-Ouates
Foundation Date:
November 2021
Technology:
Sectors: